GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SOFIVA GENOMICS Co Ltd (ROCO:6615) » Definitions » Revenue

SOFIVA GENOMICS Co (ROCO:6615) Revenue : NT$453.3 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is SOFIVA GENOMICS Co Revenue?

SOFIVA GENOMICS Co's revenue for the three months ended in Dec. 2024 was NT$103.5 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2024 was NT$453.3 Mil. SOFIVA GENOMICS Co's Revenue per Share for the three months ended in Dec. 2024 was NT$4.79. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was NT$20.97.

Warning Sign:

SOFIVA GENOMICS Co Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of SOFIVA GENOMICS Co was -4.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -4.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -2.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was -4.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 12 years, SOFIVA GENOMICS Co's highest 3-Year average Revenue per Share Growth Rate was 35.50% per year. The lowest was -16.40% per year. And the median was -0.80% per year.


SOFIVA GENOMICS Co Revenue Historical Data

The historical data trend for SOFIVA GENOMICS Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SOFIVA GENOMICS Co Revenue Chart

SOFIVA GENOMICS Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 488.87 508.42 495.78 466.80 453.31

SOFIVA GENOMICS Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 114.82 121.03 122.57 106.25 103.47

Competitive Comparison of SOFIVA GENOMICS Co's Revenue

For the Diagnostics & Research subindustry, SOFIVA GENOMICS Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SOFIVA GENOMICS Co's Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SOFIVA GENOMICS Co's Revenue distribution charts can be found below:

* The bar in red indicates where SOFIVA GENOMICS Co's Revenue falls into.


;
;

SOFIVA GENOMICS Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$453.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SOFIVA GENOMICS Co  (ROCO:6615) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


SOFIVA GENOMICS Co Revenue Related Terms

Thank you for viewing the detailed overview of SOFIVA GENOMICS Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


SOFIVA GENOMICS Co Business Description

Traded in Other Exchanges
N/A
Address
No. 66-1, Sec. 1, Chongqing S. Road, 4th Floor, Zhongzheng District, Taipei, TWN, 10043
SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, pre-natal and neonatal genetic testing and medical testing and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.

SOFIVA GENOMICS Co Headlines

No Headlines